Colorectal carcinoma
Drug research and approvals for colorectal carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,173 studies of colorectal carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 1,173
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
- Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN)NCT07947472 · Not reported · Centre Hospitalier Intercommunal Creteil · starts Nov 9, 2026
- Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA)NCT07938385 · Not reported · Royal Marsden NHS Foundation Trust · starts May 20, 2022
- Multicenter Study of SIS Patch in High-risk Colorectal AnastomosisNCT07931300 · Not applicable · Beijing Chao Yang Hospital · starts Jan 1, 2025
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerNCT07927998 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Nov 4, 2026
- A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of…NCT07919418 · Not reported · Peking Union Medical College Hospital · starts May 24, 2025
- Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer…NCT07917104 · Phase 2 · Fudan University · starts Nov 1, 2026
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal CancerNCT07913802 · Not reported · Vorarlberg Institute for Vascular Investigation and Treatment · starts Oct 23, 2023
- Development and Utilization of an Integrated Clinical Genomic DatabaseNCT07911267 · Not reported · Samsung Medical Center · starts Dec 6, 2024
How its trials ended
4,766 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 962 whose ending is known, 34% met their primary endpoint, 13% missed it and 53% stopped early.
- Completed, result not reported1,71436%
- Ongoing1,25926%
- Status unknown83117%
- Met its primary endpoint3307%
- Stopped: other or unclear2495%
- Stopped: enrollment or feasibility1303%
- Missed its primary endpoint1223%
- Stopped: sponsor or business decision701%
- Stopped: lack of efficacy411%
- Stopped: funding15<1%
- Stopped: safety5<1%
| Sep 11, 2025 | In vivo lung perfusion (IVLP) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOxaliplatin / Methylprednisolone / Cefazolin / Heparin / Human serum albumin | University Health Network | Closed |
| Jun 5, 2024 | A phase 1a/1b, first-in-human, multicenter study to assess the efficacy and safety of RGT-61159 for treatment of patients with relapsed/refractory adenoid…RGT-61159 | Rgenta Therapeutics Inc. | Ongoing |
| Nov 22, 2022 | A phase 1 study of BMS-986360/CC-90001 alone and in combination with chemotherapy or nivolumab in advanced solid tumorsCC-90001 (BMS-986360) / Nivolumab / Docetaxel / Capecitabine | Bristol-Myers Squibb | Closed |
| Feb 24, 2021 | In vivo lung perfusion (IVLP) as an adjuvant treatment for patients with resectable or unresectable pulmonary metastases of colorectal carcinomasOxaliplatin | University Health Network | Ongoing |
| Mar 9, 2016 | A phase 1/1b, open-label, multicenter, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with atezolizumab in patients with…Ciforadenant (CPI-444) / Atezolizumab | Corvus Pharmaceuticals | Closed |
| Dec 23, 2015 | A phase III study of pembrolizumab (MK-3475) vs chemotherapy in microsatellite instability-high (msi-h) or mismatch repair deficient (DMMR) stage iv colorectal…Keytruda | Merck & Co. (MSD) | Ongoing |
| Sep 30, 2015 | A phase II study of pembrolizumab (MK-3475) as monotherapy in subjects with previously treated locally advanced unresectable or metastatic (stage iv)…Keytruda | Merck & Co. (MSD) | Ongoing |
| Aug 14, 2013 | A phase 1 study to evaluate the safety, tolerability and efficacy of MK-8353 combination therapies in subjects with advanced solid tumorsMK-8353/ Ridaforolimus (MK-8669)/ Pembrolizumab (MK-3475) | Merck & Co. (MSD) | Pending |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Feb 6, 1990 | Indium In-111 altumomab pentetateDetection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma. | Hybritech, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA